2021 has been an exceptional year for Bioperfectus. We have successfully achieved many milestones by supplying our molecular diagnostic products to where people need them most. The glorious stories and moments shaped 2021 of Bioperfectus, now come and follow us for our special #2021Review.
Bioperfectus is pleased to announce that we have obtained CE Mark for our Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test).
As a leading manufacturer of molecular diagnostic solutions for infectious diseases, Biopertectus is very proud to announce today that the new SARS-CoV-2 Variant Omicron (B.1.1.529) Real-Time PCR Kit is launched globally. With the detection of the mutation sites of H655Y, N679K, P681H, and E484A, this new kit could help to identify the Omicron variant conveniently and effectively.
We are proud to inform you that a new member is joining in Bioperfectus extraction solution pipeline.
The spread of the new variant “Omicron” is faster than expected. The countries and regions with reported Omicron cases on the GISAID website have been increased to twenty-one on Dec. 2, 2021. This data only shows the number of submitted sequenced cases, which may be just the tip of the iceberg.
Bioperfectus is proud to announce that Novel Corona Virus (SARS-CoV-2) Ag Rapid Test was approved by the Ministry of Health Israel.
Today, an estimated 37.7 million people are living with HIV at the end of 2020 worldwide, among which 680,000 people died from HIV-related causes.
Scientists in South Africa on November 24, 2021, identified a concerning new variant of the coronavirus, whose mutations mark a "big jump in evolution" that is driving a spike in new cases.
Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.
What makes the world go bright, is the love, is the hope.
